GlyTherix Ltd (GlyTherix) has announced that a consortium led by the company are the successful recipients of a competitive grant in Round 9 of the Federal Government’s Cooperative Research Centres Projects (CRC-P) program.
The grant will use the company’s proprietary novel target, Glypican-1, and its lead antibody to this target, Miltuximab®, as a flagship molecule to develop national capability in manufacturing and distribution of radioimmuno-oncology drugs.
The UTS Biomanufacturing Immersion Facility will be used to manufacture antibodies for the first time.
Dr Andrew Groth, UTS Faculty of Science Business Development Manager stated the partnership was a globally significant development and the production of antibodies in the UTS Biomanufacturing Immersion Facility demonstrates the power of university and industry collaboration.
“UTS is extremely proud to be part of what is a landmark for the Australian biopharmaceutical industry with an end-to-end project from development to clinical trials,” he said.